BioAge Labs Raises $10.9M, Partners with Estonian Genome Center to Develop Anti-Aging Drugs

Sep 14, 2017

|

Premium

NEW YORK (GenomeWeb) – BioAge Labs, an early-stage drug discovery firm, recently raised $10.9 million to develop therapies that could extend a person's lifespan.

The Berkeley, California-based company has also partnered with the Estonian Genome Center to access various data related to long-lived individuals in the northern European country, which has enabled BioAge to craft bioinformatic tools that it claims can identify the molecular signatures of aging.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Moving Forward With Migrant DNA Collection Plans

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher Dies

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Just Another Diet

A Washington Post columnist writes that she is skeptical about DNA-based diets.

PNAS Studies Tackle GI Tumors, GenBank, Lung Cancer Mouse Models

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.

Featured White Papers

Cell-Based Therapies – Be on the Safe Side

Poster: Next Generation Cellular Therapeutic Technologies — Rapid Detection of Bacterial Contamination

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Nov

13

Featured Webinar

Targeted Detection of MET and NTRK Oncogenic Variants in Routine Molecular Analysis

This webinar will discuss advances in detecting MET and NTRK variants in tumor samples, which can help clinicians determine the appropriate therapy for cancer patients.

Dec

10

Featured Webinar

Maximizing Diagnostic Yield with an Optimized Variant Interpretation Platform

This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.

Menu